Philogen SpA (MIL:PHIL) Insider Ownership : 0.00 % (As of May. 07, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Philogen SpA's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Philogen SpA's Institutional Ownership is 5.19%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Philogen SpA's Float Percentage Of Total Shares Outstanding is 0.00%.

Philogen SpA Insider Ownership Historical Data

The historical data trend for Philogen SpA's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA Insider Ownership Chart

Philogen SpA Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Insider Ownership

Philogen SpA Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Insider Ownership	Get a 7-Day Free Trial					-	-	-	-	-

Philogen SpA Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Philogen SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (MIL:PHIL) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

78Q:Germany

Address

Piazza La Lizza No. 7, Siena, ITA, 53100

Website

https://www.philogen.com

Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.